Our reviews
| Status | Stage |
|---|---|
- <i> Wolbachia</i>-carrying <i>Aedes </i>mosquitoes for preventing dengue infection
- Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals
- Accuracy of measures for antiretroviral adherence in people living with HIV
- Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2
- Active case finding in contacts of people with tuberculosis
- Adding rapid diagnostic tests to community-based programmes for treating malaria
- Adjunctive steroid therapy for managing pulmonary tuberculosis
- Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis
- Amodiaquine for treating malaria
- Anthelmintic drugs for treating ascariasis
- Anthelmintics for people with neurocysticercosis
- Antiamoebic drugs for treating amoebic colitis
- Antibiotic therapy for Shigella dysentery
- Antibiotic treatment for travellers' diarrhoea
- Antibiotic treatment to reduce the duration and severity of travellers’ diarrhoea
- Antibiotics for treating human brucellosis
- Antibiotics for treating scrub typhus
- Antibody tests for identification of current and past infection with SARS-CoV-2
- Antihelminthics in helminth-endemic areas: effects on HIV disease progression
- Antimicrobial drugs for treating cholera
- Antimicrobials for treating symptomatic non-typhoidal infection
- Antipyretic measures for treating fever in malaria
- Antiretroviral resistance testing in HIV-positive people
- Artemether for severe malaria
- Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria
- Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria
- Artemisinin derivatives for treating severe malaria
- Artemisinin derivatives for treating uncomplicated malaria
- Artemisinin-based combination therapy for treating uncomplicated malaria
- Artemisinin-based combination therapy for treating uncomplicated malaria
- Artemisinin-naphthoquine for treating uncomplicated malaria
- Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria
- Artesunate versus quinine for treating severe malaria
- Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria
- Azithromycin for treating uncomplicated malaria
- Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhoea and severe dehydration in children
- Biannual praziquantel treatment for schistosomiasis
- Blood transfusion for treating malarial anaemia
- Chemotherapy for second-stage Human African trypanosomiasis
- Chemotherapy for second-stage human African trypanosomiasis: drugs in use
- Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria
- Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19
- Chlorproguanil-dapsone for treating uncomplicated malaria
- Circulating antigen tests and urine reagent strips for diagnosis of active schistosomiasis in endemic areas
- Combined and alternating paracetamol and ibuprofen therapy for febrile children
- Community animal health services for improving household wealth and health status of low income farmers
- Community views on active case finding for tuberculosis in low- and middle-income countries: a qualitative evidence synthesis
- Community views on mass drug administration for filariasis: a qualitative evidence synthesis
- Community views on mass drug administration for soil-transmitted helminths: a qualitative evidence synthesis
- Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low- and moderate-incidence populations
- Control methods for and
- Corticosteroids for dengue infection
- Corticosteroids for managing tuberculous meningitis
- Corticosteroids for tuberculous pleurisy
- Diagnosis of SARS-CoV-2 infection and COVID-19: accuracy of signs and symptoms; molecular, antigen, and antibody tests; and routine laboratory markers
- Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis
- Digital devices for tuberculosis treatment adherence
- Dihydroartemisinin-piperaquine for treating uncomplicated malaria
- Directly observed therapy for treating tuberculosis
- Drug therapy for Mycetoma
- Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
- Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis
- Drugs for treating infection
- Drugs for treating Buruli ulcer ( disease)
- Drugs for treating giardiasis
- Drugs for treating paracoccidioidomycosis
- Drugs for treating uncomplicated malaria in pregnant women
- Drugs for treating urinary schistosomiasis
- Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
- Early versus Delayed Refeeding for Children with Acute Diarrhoea
- Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals
- Electronic and animal noses for detecting SARS-CoV-2 infection
- Electronic mosquito repellents for preventing mosquito bites and malaria infection
- Favipiravir for treating COVID-19
- Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis
- Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)
- Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
- Fly control to prevent diarrhoea in children
- Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas
- Fully intermittent dosing with drugs for treating tuberculosis in adults
- GenoType MTBDRassay for resistance to second-line anti-tuberculosis drugs
- Glucose-6-phosphate dehydrogenase deficiency near-patient tests for tafenoquine or primaquine use with Plasmodium vivax malaria
- Hand cleaning with ash for reducing the spread of viral and bacterial infections: a rapid review
- Hand-washing promotion for preventing diarrhoea
- High first dose quinine regimen for treating severe malaria
- House modifications for preventing malaria
- Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV
- Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis
- Incentives and enablers to improve adherence in tuberculosis
- Indoor residual spraying for preventing malaria
- Indoor residual spraying for preventing malaria in communities using insecticide-treated nets
- Insecticide space spraying for preventing malaria transmission
- Insecticide-treated nets for preventing malaria
- Insecticide-treated nets for preventing malaria in pregnancy
- Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults
- Intermittent preventive antimalarial treatment for children with anaemia
- Intermittent preventive treatment for malaria in children living in areas with seasonal transmission
- Intermittent preventive treatment for malaria in infants
- Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women
- Intermittent versus daily therapy for treating tuberculosis in children
- Interventions for preventing reactions to snake antivenom
- Interventions for treating melioidosis
- Interventions for treating scabies
- Interventions for treating trichomoniasis in women
- Interventions for treating tuberculous pericarditis
- Interventions to improve disposal of child faeces for preventing diarrhoea and soil-transmitted helminth infection
- Interventions to improve disposal of human excreta for preventing diarrhoea
- Interventions to improve sanitation for preventing diarrhoea
- Interventions to improve water quality for preventing diarrhoea
- Interventions to improve water, sanitation, and hygiene for preventing soil-transmitted helminth infection
- Interventions to increase tuberculosis case detection at primary healthcare or community-level services
- Intramuscular arteether for treating severe malaria
- Intrarectal quinine versus intravenous or intramuscular quinine for treating malaria
- Iron-chelating agents for treating malaria
- Isoniazid for preventing tuberculosis in HIV-infected children
- Isoniazid for preventing tuberculosis in non-HIV infected persons
- Ivermectin and permethrin for treating scabies
- Ivermectin for preventing and treating COVID-19
- Ivermectin treatment in humans for reducing malaria transmission
- Ivermectin versus albendazole or thiabendazole for infection
- Laboratory tests for diagnosis of congenital Zika virus in fetuses and neonates
- Lactose avoidance for young children with acute diarrhoea
- Larviciding to prevent malaria transmission
- Larvivorous fish for preventing malaria transmission
- Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV
- Linezolid for drug-resistant pulmonary tuberculosis
- Low level laser therapy for treating tuberculosis
- Malaria chemoprophylaxis in sickle cell disease
- Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria
- Mass drug administration for malaria
- Mefloquine for preventing malaria during travel to endemic areas
- Mefloquine for preventing malaria in pregnant women
- Methylene blue for treating malaria
- Micronutrient supplementation in adults with HIV infection
- Molnupiravir for treating COVID-19
- Mosquito aquatic habitat modification and manipulation interventions to control malaria
- Mosquito repellents for malaria prevention
- MVA85A vaccine to enhance BCG for preventing tuberculosis
- Mycobacterium vaccae immunotherapy for treating tuberculosis
- Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
- Nutritional supplements for patients being treated for active visceral leishmaniasis
- Nutritional supplements for people being treated for active tuberculosis
- Oral iron supplements for children in malaria-endemic areas
- Oral killed cholera vaccines for preventing cholera
- Oral rehydration salt solution for treating cholera: ≤ 270 mOsm/L solutions vs ≥ 310 mOsm/L solutions
- Oral vaccines for preventing cholera
- Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children
- Oral zinc for treating diarrhoea in children
- Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children
- Paracetamol versus placebo or physical methods for treating fever in children
- Parallel use of low-complexity automated nucleic acid amplification tests and lateral flow urine lipoarabinomannan assays to detect tuberculosis disease in adults and adolescents living with HIV
- Parallel use of low-complexity automated nucleic acid amplification tests on respiratory samples and stool with or without lateral flow lipoarabinomannan assays to detect pulmonary tuberculosis disease in children
- Patient education and counselling for promoting adherence to treatment for tuberculosis
- Physical methods versus drug placebo or no treatment for managing fever in children
- Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
- Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition
- Point-of-care tests detecting HIV nucleic acids for diagnosis of HIV-1 or HIV-2 infection in infants and children aged 18 months or less
- Point-of-care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities
- Polymer-based oral rehydration solution for treating acute watery diarrhoea
- Pre-referral rectal artesunate for severe malaria
- Primaquine alternative dosing schedules for preventing malaria relapse in people with
- Primaquine for preventing relapse in people with malaria treated with chloroquine
- Primaquine or other 8-aminoquinolines for reducing transmission
- Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people
- Probiotics for treating acute infectious diarrhoea
- Probiotics for treating persistent diarrhoea in children
- Prognostic accuracy of imaging findings for predicting morbidity and mortality in patients with COVID-19
- Psychosocial group interventions to improve psychological well-being in adults living with HIV
- Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
- Pyronaridine-artesunate for treating uncomplicated <i>Plasmodium falciparum</i> malaria
- Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review
- Racecadotril for acute diarrhoea in children
- Rapid diagnostic tests for malaria in endemic countries
- Rapid diagnostic tests for diagnosing uncomplicated malaria in endemic countries
- Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or malaria in endemic countries
- Rapid diagnostic tests for plague
- Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever
- Rapid diagnostic tests versus clinical diagnosis for managing people with fever in malaria endemic settings
- Rapid initiation of antiretroviral therapy for people living with HIV
- Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views
- Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease
- Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection
- Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection
- Reduced osmolarity oral rehydration solution for treating dehydration caused by acute diarrhoea in children
- Regimens of less than six months for treating tuberculosis
- Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment
- Ribavirin for treating Crimean Congo haemorrhagic fever
- Rifabutin for treating pulmonary tuberculosis
- Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB
- Rotavirus vaccine for preventing diarrhoea
- Routine anticonvulsants for treating cerebral malaria
- Routine laboratory testing to determine if a patient has COVID-19
- Routine surgery in addition to chemotherapy for treating spinal tuberculosis
- School-based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents
- Screening tests for active pulmonary tuberculosis in children
- Selected laboratory-based biomarkers for assessing vitamin A deficiency in at-risk individuals
- Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis
- Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19
- Six months therapy for tuberculous meningitis
- Six-month therapy for abdominal tuberculosis
- Smectite for acute infectious diarrhoea in children
- Steroids for treating cerebral malaria
- Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria
- Symptom screening for active tuberculosis in pregnant women living with HIV
- Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status
- Tafenoquine for preventing relapse in people with <i>Plasmodium vivax</i> malaria
- TB-LAMP (loop-mediated isothermal amplification) for diagnosing pulmonary tuberculosis in children
- Therapeutics for treating mpox in humans
- Thoracic imaging tests for the diagnosis of COVID-19
- Topical repellents for malaria prevention
- Treating BCG-induced disease in children
- Treating progressive disseminated histoplasmosis in people living with HIV
- Treatment for HIV-associated cryptococcal meningitis
- Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins
- Treatment of uncomplicated hepatic cystic echinococcosis (hydatid disease)
- Typhoid conjugate vaccines for preventing typhoid fever (enteric fever)
- Unit-dose packaged drugs for treating malaria
- Vaccines for preventing anthrax
- Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected)
- Vaccines for preventing enterotoxigenic (ETEC) diarrhoea
- Vaccines for preventing Japanese encephalitis
- Vaccines for preventing malaria (blood-stage)
- Vaccines for preventing malaria (pre-erythrocytic)
- Vaccines for preventing malaria (SPf66)
- Vaccines for preventing plague
- Vaccines for preventing rotavirus diarrhoea: vaccines in use
- Vaccines for preventing smallpox
- Vaccines for preventing tick-borne encephalitis
- Vaccines for preventing typhoid fever
- Vector and reservoir control for preventing leishmaniasis
- Vitamin A supplements for reducing mother-to-child HIV transmission
- Vitamin D supplementation for preventing infections in children under five years of age
- Volatile pyrethroid spatial repellents for malaria prevention
- Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms
- Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults
- Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children
- Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
- Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis
- Can international travel-related control measures contain the spread of the COVID-19 pandemic?
- How accurate are different types of sample collection for diagnosing COVID-19 infection?
- How accurate are Truenat assays for detecting pulmonary tuberculosis and rifampicin resistance in adults and adolescents?New
- Interventions for treating head lice: a network meta-analysis
- Interventions to increase COVID-19 vaccine uptake
- Pharmacological and psychological interventions for depression in people with tuberculosis
- Renin-angiotensin system inhibitors for treating COVID-19 in adults
- What is the best way to support resilience and mental well-being in frontline healthcare professionals during and after a pandemic?
- COVID-19 (19)
- Can international travel-related control measures contain the spread of the COVID-19 pandemic?
- Diagnosis of SARS-CoV-2 infection and COVID-19: accuracy of signs and symptoms; molecular, antigen, and antibody tests; and routine laboratory markers
- Hand cleaning with ash for reducing the spread of viral and bacterial infections: a rapid review
- Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review
- Electronic and animal noses for detecting SARS-CoV-2 infection
- How accurate are different types of sample collection for diagnosing COVID-19 infection?
- Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection
- Routine laboratory testing to determine if a patient has COVID-19
- Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2
- Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19
- Thoracic imaging tests for the diagnosis of COVID-19
- Interventions to increase COVID-19 vaccine uptake
- Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19
- Favipiravir for treating COVID-19
- Ivermectin for preventing and treating COVID-19
- Prognostic accuracy of imaging findings for predicting morbidity and mortality in patients with COVID-19
- Renin-angiotensin system inhibitors for treating COVID-19 in adults
- What is the best way to support resilience and mental well-being in frontline healthcare professionals during and after a pandemic?
- Antibody tests for identification of current and past infection with SARS-CoV-2
- HIV (18)
- Diagnostics (4)
- Accuracy of measures for antiretroviral adherence in people living with HIV
- Point-of-care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities
- Point-of-care tests detecting HIV nucleic acids for diagnosis of HIV-1 or HIV-2 infection in infants and children aged 18 months or less
- Symptom screening for active tuberculosis in pregnant women living with HIV
- Prevention (4)
- Isoniazid for preventing tuberculosis in HIV-infected children
- Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people
- School-based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents
- Vitamin A supplements for reducing mother-to-child HIV transmission
- Treatment (8)
- Antihelminthics in helminth-endemic areas: effects on HIV disease progression
- Antiretroviral resistance testing in HIV-positive people
- Psychosocial group interventions to improve psychological well-being in adults living with HIV
- Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals
- Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults
- Micronutrient supplementation in adults with HIV infection
- Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis
- Treatment for HIV-associated cryptococcal meningitis
- Delivery strategies (2)
- Diagnostics (4)
- Malaria (76)
- Diagnostics (5)
- Glucose-6-phosphate dehydrogenase deficiency near-patient tests for tafenoquine or primaquine use with Plasmodium vivax malaria
- Rapid diagnostic tests for diagnosing uncomplicated malaria in endemic countries
- Rapid diagnostic tests versus clinical diagnosis for managing people with fever in malaria endemic settings
- Rapid diagnostic tests for malaria in endemic countries
- Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or malaria in endemic countries
- Prevention (29)
- Vaccines (3)
- Vector Control (14)
- Indoor residual spraying for preventing malaria in communities using insecticide-treated nets
- Electronic mosquito repellents for preventing mosquito bites and malaria infection
- Larvivorous fish for preventing malaria transmission
- House modifications for preventing malaria
- Indoor residual spraying for preventing malaria
- Insecticide space spraying for preventing malaria transmission
- Insecticide-treated nets for preventing malaria
- Insecticide-treated nets for preventing malaria in pregnancy
- Larviciding to prevent malaria transmission
- Mosquito repellents for malaria prevention
- Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa
- Volatile pyrethroid spatial repellents for malaria prevention
- Topical repellents for malaria prevention
- Mosquito aquatic habitat modification and manipulation interventions to control malaria
- Drugs for prevention for people living in endemic areas (11)
- Primaquine or other 8-aminoquinolines for reducing transmission
- Intermittent preventive treatment for malaria in children living in areas with seasonal transmission
- Intermittent preventive treatment for malaria in infants
- Mass drug administration for malaria
- Intermittent preventive antimalarial treatment for children with anaemia
- Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women
- Malaria chemoprophylaxis in sickle cell disease
- Ivermectin treatment in humans for reducing malaria transmission
- Mefloquine for preventing malaria in pregnant women
- Primaquine alternative dosing schedules for preventing malaria relapse in people with
- Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
- Drugs for prevention for travellers (1)
- Treatment (39)
- Treatment of uncomplicated falciparum malaria (21)
- Single agent (5)
- Combined treatment, non-artemisinin based (3)
- Combined treatment, artemisinin based (12)
- Mass drug administration for malaria
- Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria
- Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria
- Artemisinin derivatives for treating severe malaria
- Artemisinin derivatives for treating uncomplicated malaria
- Artemisinin-based combination therapy for treating uncomplicated malaria
- Artemisinin-naphthoquine for treating uncomplicated malaria
- Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria
- Dihydroartemisinin-piperaquine for treating uncomplicated malaria
- Adding rapid diagnostic tests to community-based programmes for treating malaria
- Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria
- Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children
- Drugs for treatment in special groups (1)
- Treatment of vivax malaria (3)
- Treatment of severe malaria (7)
- Artemether for severe malaria
- Artemisinin derivatives for treating severe malaria
- Artesunate versus quinine for treating severe malaria
- High first dose quinine regimen for treating severe malaria
- Intramuscular arteether for treating severe malaria
- Intrarectal quinine versus intravenous or intramuscular quinine for treating malaria
- Pre-referral rectal artesunate for severe malaria
- Adjunctive treatment of severe malaria (5)
- Symptomatic treatment (3)
- Treatment of uncomplicated falciparum malaria (21)
- Delivery strategies (3)
- Diagnostics (5)
- Tuberculosis (50)
- Diagnostics (15)
- Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals
- Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis
- Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status
- Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms
- Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults
- How accurate are Truenat assays for detecting pulmonary tuberculosis and rifampicin resistance in adults and adolescents?New
- Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV
- Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV
- Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views
- Screening tests for active pulmonary tuberculosis in children
- Symptom screening for active tuberculosis in pregnant women living with HIV
- GenoType MTBDRassay for resistance to second-line anti-tuberculosis drugs
- Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
- Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis
- Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children
- Prevention (6)
- Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB
- Isoniazid for preventing tuberculosis in non-HIV infected persons
- Isoniazid for preventing tuberculosis in HIV-infected children
- MVA85A vaccine to enhance BCG for preventing tuberculosis
- Mycobacterium vaccae immunotherapy for treating tuberculosis
- Treating BCG-induced disease in children
- Treatment (18)
- Drugs (15)
- Adjunctive steroid therapy for managing pulmonary tuberculosis
- Corticosteroids for managing tuberculous meningitis
- Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis
- Linezolid for drug-resistant pulmonary tuberculosis
- Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis
- Pharmacological and psychological interventions for depression in people with tuberculosis
- Regimens of less than six months for treating tuberculosis
- Rifabutin for treating pulmonary tuberculosis
- Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis
- Six-month therapy for abdominal tuberculosis
- Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)
- Fully intermittent dosing with drugs for treating tuberculosis in adults
- Interventions for treating tuberculous pericarditis
- Intermittent versus daily therapy for treating tuberculosis in children
- Corticosteroids for tuberculous pleurisy
- Other (3)
- Drugs (15)
- Delivery strategies (11)
- Contact tracing strategies in household and congregate environments to identify cases of tuberculosis in low- and moderate-incidence populations
- Patient education and counselling for promoting adherence to treatment for tuberculosis
- Digital devices for tuberculosis treatment adherence
- Directly observed therapy for treating tuberculosis
- Incentives and enablers to improve adherence in tuberculosis
- Interventions to increase tuberculosis case detection at primary healthcare or community-level services
- Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment
- Active case finding in contacts of people with tuberculosis
- Six months therapy for tuberculous meningitis
- Six-month therapy for abdominal tuberculosis
- Community views on active case finding for tuberculosis in low- and middle-income countries: a qualitative evidence synthesis
- Diagnostics (15)
- Diarrhoeal infections (32)
- Principles of prevention and management (21)
- Prevention (7)
- Hand-washing promotion for preventing diarrhoea
- Fly control to prevent diarrhoea in children
- Interventions to improve disposal of child faeces for preventing diarrhoea and soil-transmitted helminth infection
- Interventions to improve disposal of human excreta for preventing diarrhoea
- Interventions to improve sanitation for preventing diarrhoea
- Interventions to improve water quality for preventing diarrhoea
- Interventions to improve water, sanitation, and hygiene for preventing soil-transmitted helminth infection
- Rehydration (4)
- Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhoea and severe dehydration in children
- Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children
- Polymer-based oral rehydration solution for treating acute watery diarrhoea
- Reduced osmolarity oral rehydration solution for treating dehydration caused by acute diarrhoea in children
- Anti-infective treatment (4)
- Management (6)
- Antibiotic treatment to reduce the duration and severity of travellers’ diarrhoea
- Oral zinc for treating diarrhoea in children
- Racecadotril for acute diarrhoea in children
- Early versus Delayed Refeeding for Children with Acute Diarrhoea
- Smectite for acute infectious diarrhoea in children
- Lactose avoidance for young children with acute diarrhoea
- Prevention (7)
- Prevention and management of specific infections (11)
- Cholera (6)
- Antimicrobial drugs for treating cholera
- Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected)
- Oral killed cholera vaccines for preventing cholera
- Oral rehydration salt solution for treating cholera: ≤ 270 mOsm/L solutions vs ≥ 310 mOsm/L solutions
- Oral vaccines for preventing cholera
- Vaccines for preventing enterotoxigenic (ETEC) diarrhoea
- Giardiasis (1)
- Rotavirus (2)
- Salmonellosis (1)
- Shigellosis (1)
- Cholera (6)
- Principles of prevention and management (21)
- Neglected tropical diseases (19)
- Buruli ulcer (1)
- Human African Trypanosomiasis (2)
- Lymphatic filariasis (3)
- Mycetoma (1)
- Schistosomiasis (4)
- Visceral leishmaniasis (3)
- Cysticercosis (1)
- Dengue (3)
- Diagnosis (0)
- Prevention (2)
- Treatment (1)
- Helminths, soil transmitted (1)
- Other (32)
- Angiostrongylus (0)
- Anthrax (1)
- Antimicrobial resistance (1)
- Ascariasis (1)
- Brucellosis (1)
- Crimean Congo haemorrhagic fever (1)
- Epidemic typhus (0)
- Fever management (3)
- Food supplements for preventing infections (1)
- Gnathostomiasis (0)
- Headlice (1)
- Histoplasmosis (1)
- Biomarkers for vitamin deficiency (1)
- Japanese encephalitis (1)
- Melioidosis (1)
- Paracoccidioidomycosis (1)
- Paraveterinary services impact on human health (1)
- Plague (2)
- Scabies (2)
- Scrub typhus (1)
- Smallpox (1)
- Snake bites (1)
- Strongyloidiasis (1)
- Tick-borne encephalitis (1)
- Trichomoniasis (1)
- Typhoid and paratyphoid fever (enteric fever) (5)
- Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins
- Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
- Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever
- Typhoid conjugate vaccines for preventing typhoid fever (enteric fever)
- Vaccines for preventing typhoid fever
- Zika (1)
Related content
The protocol for our review “Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance” was first published in 1997, prior to creation of the online Cochrane Library. A copy of this document can be found here.